

I. AMENDMENT

In the Claims:

The following Listing of Claims replaces all prior versions, and listings, of claims in the application:

Listing of the Claims:

1. (Currently Amended) A method of ~~inhibiting the growth~~inducing apoptosis of a papillomavirus-transformed cell in a hyperplastic lesion in a subject comprising topically administering to said lesion a growth inhibiting amount of a composition comprising (a) an expression cassette comprising a promoter, active in cells of said lesion, operably linked to a polynucleotide encoding a *p53* polypeptide, and (b) a pharmaceutical preparation suitable for topical delivery, wherein ~~expression of said *p53* polypeptide inhibits growth of said cell~~undergoes apoptosis.
2. (Original) The method of claim 1, wherein said subject is a mammal.
3. (Original) The method of claim 2, wherein said mammal is a human.
4. (Original) The method of claim 1, wherein said cell is a keratinocyte.
5. (Original) The method of claim 1, wherein said cell is an epithelial cell.
6. (Original) The method of claim 1, wherein said cell is a skin cell.
7. (Original) The method of claim 1, wherein said cell is a mucosal cell.
8. (Original) The method of claim 1, wherein said papillomavirus is a human papillomavirus.

9. (Original) The method of claim 1, wherein said lesion is selected from the group consisting of a squamous cell hyperplastic lesion, premalignant epithelial lesion, psoriatic lesion, cutaneous wart, periungual wart, anogenital wart, epidermodysplasia verruciformis, an intraepithelial neoplastic lesion, focal epithelial hyperplasia, conjunctival papilloma, conjunctival carcinoma, or squamous carcinoma lesion.
10. (Original) The method of claim 1, wherein said expression cassette is carried in a viral vector.
11. (Original) The method of claim 10, wherein said viral vector is an adenoviral vector, a retroviral vector, an adeno-associated viral vector, a vaccinia viral vector or a pox viral vector.
12. (Original) The method of claim 10, wherein said viral vector is an adenoviral vector.
13. (Original) The method of claim 1, wherein said expression cassette is carried in a nonviral vector.
14. (Original) The method of claim 13, wherein said non-viral vector is a lipid.
15. (Original) The method of claim 1, wherein said composition is formulated as a mouthwash or mouthrinse.
16. (Original) The method of claim 15, wherein said mouthwash further comprises a flavorant.
17. (Original) The method of claim 16, wherein said flavorant is selected from the group comprising one or more flavor components selected from wintergreen oil, oregano oil, bay leaf oil, peppermint oil, spearmint oil, clove oil, sage oil, saffron oil, lemon oil, orange oil, anise oil, benzaldehyde, bitter almond oil, camphor, cedar leaf oil, marjoram oil, citronella oil, lavender oil, mustard oil, pine oil, pine needle oil, rosemary oil, thyme oil, cinnamon leaf oil, and mixtures thereof.

18. (Currently Amended) The method of claim 1, wherein said composition is formulated as a ~~douche~~ solution.
19. (Original) The method of claim 1, wherein said composition is formulated as an ointment or salve.
20. (Original) The method of claim 1, wherein said composition is formulated as a cream for topical, anal or vaginal delivery.
21. (Original) The method of claim 1, wherein said composition is formulated as a spray or aerosol.
22. (Original) The method of claim 1, wherein said composition is formulated as a suppository for anal or vaginal delivery.
23. (Original) The method of claim 1, wherein the promoter is a constitutive promoter, an inducible promoter or a tissue specific promoter.
24. (Original) The method of claim 1, wherein inhibiting growth comprises in slowing or halting the growth of said lesion.
25. (Original) The method of claim 1, wherein inhibiting growth comprises a reduction in the size of said lesion.
26. (Original) The method of claim 1, wherein inhibiting growth comprises induction of apoptosis said cells of said lesion.
27. (Original) The method of claim 1, wherein inhibiting growth comprises induction of an immune response against said cells of said lesion.

28. (Original) The method of claim 1, further comprising subjecting said subject to a secondary anti-hyperplastic therapy.

29. (Original) The method of claim 28, wherein said secondary anti-hyperplastic therapy is chemotherapy, radiotherapy, immunotherapy, phototherapy, cryotherapy, toxin therapy, hormonal therapy or surgery.

30. (Canceled)

31. (Currently Amended) A mouthwash for ~~inhibiting the growth~~inducing apoptosis of a papillomavirus-transformed cell in a hyperplastic lesion in a subject comprising (a) an expression cassette comprising a promoter operably linked to a polynucleotide encoding a *p53* polypeptide, (b) a liquid carrier formulated for oral delivery, and (c) a flavorant.

32. (Original) The mouthwash of claim 31, wherein said flavorant is selected from the group comprising one or more flavor components selected from wintergreen oil, oregano oil, bay leaf oil, peppermint oil, spearmint oil, clove oil, sage oil, sassafras oil, lemon oil, orange oil, anise oil, benzaldehyde, bitter almond oil, camphor, cedar leaf oil, marjoram oil, citronella oil, lavender oil, mustard oil, pine oil, pine needle oil, rosemary oil, thyme oil, cinnamon leaf oil, and mixtures thereof.

33. (Currently Amended) A douche solution for ~~inhibiting the growth~~inducing apoptosis of a papillomavirus-transformed cell in a hyperplastic lesion in a subject comprising (a) an expression cassette comprising a promoter operably linked to a polynucleotide encoding a *p53* polypeptide, and (b) a liquid carrier formulated for vaginal delivery.

34-60. (Canceled)